• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risks and Benefits of Current and Novel Drugs to Treat Agitation in Alzheimer's Disease
Expert Opin Drug Saf. 2022 Oct 17. doi: 10.1080/14740338.2022.2136162. Online ahead of print.ABSTRACTINTRODUCTION: At present, no pharmacological interventions have been approved for the treatment of agitation in Alzheimer's disease (AD), an important neuropsychiatric symptom that has been linked to increased mortality and greater caregiver burden. Antipsychotics offer some benefit, but increase the risk of adverse events such as falls, extrapyramidal symptoms, stroke, and mortality. Over the past 10 years, several new and repurposed medications have shown promise for treating AD-associated agitation.AREAS COVERED: We revi...
Source: Expert Opinion on Drug Safety - October 17, 2022 Category: Drugs & Pharmacology Authors: Nathan Herrmann Hui Jue Wang Ella Bing Xin Song Kritleen K Bawa Krista L Lanct ôt Source Type: research

Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3 β inhibitors: A critical review.
Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review. Eur J Med Chem. 2018 Dec 31;164:448-470 Authors: Xu M, Wang SL, Zhu L, Wu PY, Dai WB, Rakesh KP Abstract Glycogen Synthase Kinase-3 (GSK-3) is a constitutively dynamic, omnipresent serine/threonine protein kinase regularly called as a "multitasking kinase" due to its pliable function in diverse signaling pathways. It exists in two isoforms i.e., GSK-3α and GSK-3β. Inhibition of GSK-3 may be useful in curing various diseases such as Alzheimer's disease, type II diabetes, mood disorde...
Source: European Journal of Medicinal Chemistry - December 31, 2018 Category: Chemistry Authors: Xu M, Wang SL, Zhu L, Wu PY, Dai WB, Rakesh KP Tags: Eur J Med Chem Source Type: research